MedTrace Logo

Fluciclovine-PET/CT for Bone Metastases From Prostate Adenocarcinoma

NCT03496844 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2022-08-16

Study results available
· View outcomes & findings →

Summary

Determine diagnostic accuracy of Axumin-PET positive bone lesion by confirmatory bone biopsy.

Conditions

  • Prostate Adenocarcinoma

Interventions

DIAGNOSTIC_TEST

F-18 fluciclovine-PET/CT scan

PET/CT imaging with F-18 fluciclovine

Sponsors & Collaborators

  • Blue Earth Diagnostics

    collaborator INDUSTRY

  • Banner University Medical Center

    collaborator OTHER

  • University of Arizona

    lead OTHER

Principal Investigators

  • Phillip H Kuo, MD, PhD · University of Arizona

  • Hani Babiker, MD · University of Arizona

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-15
Primary Completion
2021-04-27
Completion
2021-04-27
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03496844 on ClinicalTrials.gov